Plaquex for Atherosclerosis
Plaquex has a whole battery of different functions in cell membranes that influence many different parameters involved in atherosclerosis.
For a quick read, here is a summary of actions that reduce Atherosclerosis. More detailed information can be found after the summary and in the book Plaquex, The Miracle Molecule.
- LDL and VLDL reduction
- HDL increase
- Triglyceride reduction
- Reduces Lipid Peroxidation
- Increases Enzyme activity such as LCAT
- Reduces Platelet Aggregation
- Improves RBC deformability
- Increases anti-oxidants (Glutathione)
- Activates Immune Cells
- Reduces Endocytosis
- Reduces Mast Cell formation
- Cell Membrane Repair
Plaquex reduces LDL Cholesterol and Triglyceride levels while it increases HDL Cholesterol levels. It is becoming very evident that elevated LDL cholesterol is NOT the cause of heart disease. In fact studies involving statins show that lowering LDL cholesterol has no influence on the rate of heart attacks. Fast CT exams show Calcium deposits in coronarly blood vessels and the rate of increase of the Calcium score over time is more predicitive for future heart attacks that LDL levels that show no correlation whatsoever. But it is hypothesized that the body uses Cholesterol as "Bandaid" to patch up damaged endothelial cells, but it is not the primary cause of the damage and the plaque. Since plaque deposits contain some cholesterol, removing it will reduce the size of the plaque.
Plaquex activates the enzyme LCAT Lecithin Acyl Cholesterol Transferase) which esterifies cholesterol, including deposits in plaque, enabling HDL to take it up and remove it from vascular walls and eliminate it through the liver.1
Effects on Total Cholesterol
In a documentation of 15 clinical trials with a duration of PC treatment between 1 and 12 months, total cholesterol was lowered 8.8% to 28.2 %. The initial values, route of administration, PC dosage and duration of the treatment determine the amount of the reduction. 11,12,13,14,15,16,17,18,19
Diabetics with hypercholesterolemia type 2b and 4 were treated with PC for 6 weeks (pink line) and observed for another 2 weeks against placebo (blue line). The treated group had a significant reduction of total cholesterol levels, but they started to climb again after stopping treatment. This shows the importance of maintenance therapy.
Effects on LDL Cholesterol
In clinical studies in 1160 patients the mean reduction of LDL cholestereol was 31%. The extent of the reduction was determined by the type of hyperlipoproteinemia, the PC dosage and the duration fo treatment. To short a treatment (14 days), to low of a dosage ( less than 1.5 grams) did not have any effect on LDL cholesterol. 20,21,22,23,24,25
LDL levels during 42 days treatment (green) with 1.9 g of PC per day against Placebo (purple).
Effects on HDL Cholesterol
In various studies an increase of HDL Cholesterol was found between 10-45%. Very low initial HDL levels were raised significantly while close to normal initial levels were hardly influenced.26-33, The effect was more pronounced in non smokers than in smokers.
HDL levels during a 6 week treatment (pink line) with 2.7 g/day against placebo (blue line). Two weeks after stopping treatment, HDL levels begin to decline, showing the importance of maintenance therapy.
Effects on Triglyceride Levels
Elevated Triglyceride levels were treated and observed in 2734 patients. The extent of the reduction was dependent on the initial levels. Very high levels were reduced significantly while close to normal levels were hardly influenced. The mean reduction was a 25% drop. The table below shows the reduction of Triglyceride levels dependent on the method of application and duration of treatment. 22,26,34-36
A correlation was found to caloric intake. The more calories the patient eats, the less the extent of the drop in Triglyceride levels.
Lipid Peroxidation 33,37-39
An important factor in the development of athersclerosis is lipid peroxidation. A close relationship was found between lipid peroxidation and increased platelet aggregation. In vivo and in vitro studies show a decrease in lipid peroxidation parameters when PC is applied. It's surmised that increased Glutathione and SOD levels help reduce/prevent lipid peroxidation.
PC reduces LDL oxidation as well. In a study the time was measured until LDL was oxidized when mixed with various forms of PC or alpha tocopherol as well as an oxidizing agent. When LDL was incubated with unsaturated PC as in Plaquex, the lag time until it oxidized was much longer than with all other forms of PC or alpha Tocopherol.
Effects on Enzymes involved with lipid metabolism
The most important enzyme is LCAT. It's synthesized in the liver. It catalyzes the esterification of free cholesterol, including cholesterol in plaques and in cell membranes, so it can be taken up by HDL and transported to the liver for elimination. PC with saturated fatty acid chains such as from egg yolk diminish the activity of LCAT while PC with unsaturated fatty acid chains activates LCAT. 2,3,5,4,5,6,7,8,9 Other enzymes activated by polyunsaturated PC are Lipoprotein Lipase and hepatic Triglyceride Lipase.10
Reduced Platelet Aggregation 30, 40-48
There is a close relationship between high cholesterol levels in the membranes of platelets and an increased tendency to adhesion and aggregation of platelets.40 Deposits of platelets on vascular walls enhance the sensitivity of the wall towards substances released from platelets, increasing the wall permeability, leading to deposits of plasma constituents such as lipids in the injured wall. Plaquex, through the activation of LCAT, reduces the amount of cholesterol in the membranes of platelets, thereby reducing their tendency to adhesion and aggregation. During a 14 day trial with 500 mg PC/day given as infusions, the reactive platelet aggregation was reduced by 60%. A further study using 250mg/day over a period of 30 days in elderly patients with increased tendency to coagulation showed fibrinolytic acitivity to increase in the thrombo-elastogram. 1.5 g oral PC over 16 weeks increased serum 6-keto-PGF1, a stabilized metabolite of the antiaggregatory and vasodilatory prostaglandin PGI2 and a drop in Thromboxane levels. 49
Improved Deformability of Red Blood Cells
Increased accumulation of cholesterol in RBC membranes impair the fluidity and functioning of the membrane and RBC deformability, making it hard for RBCs to pass through tight capillaries. An improved passage of red blood cells through microfilters and the normalisation of RBC aggregation was found in patients given 500mg by IV injection and taking 1.8 g orally/day for three months. Studies confirmed that an increase in LCAT activity lowered the cholesterol content in the membranes of red blood cells, thereby making the membranes more fluid and deformable. 28,40,50,51,52
Effects on Inflammatory Parameters
Studies showed a reduction of inflammatory parameters Interleukin 6 and 10, Tumor Necrosis Factor alpha as well as Nuclear Factor Kappa when animals of various species were given PC. 53, 54
Effects on Antioxidants
Plaquex increases the levels of Glutathione and Sodium Oxide Dismutase by increasing the enzymes in the cell membranes responsible for these antioxidants. It thereby combats lipid peroxidation and prevents alcohol induced liver fibrosis by inhibiting alcohol induced oxidative stress. 55-57
Activation of Immune Cells
Immune cells require unsaturated PC in their membranes in order to activate58-60,. It is surmised that the activation of immune cells could take down bacterial biofilms found in vascular plaque deposits.
Reduced Endocytosis 61 and Mast Cell Formation 62
Plaquex inhibits endocytosis in smooth muscle cells thereby preventing the formation of atherosclerotic plaque. Bowyer et al (69) described a highly significant inhibition of endocytosis in the smooth muscle cells of pig aortas after in vitro incubation with PC. According to the authors, these results suggest that PC inhibits atherogenic processes by reducing the endocytosis of plasma constituents. It also educes the accumulation of cholesterol in macrophages by 15-20%, thereby preventing the formation of foam cells.
Reduction of Atherosclerosis
The combination effects on lipids, LCAT, antioxidation, antiinflammation, inhibition of endocytosis, immune cell activation, reduced platelet aggregation and enhanced RBS deformability reduce atherosclerotic plaque deposits. In total 22 studies in 7 animal models were done and they showed prevention of atherosclerosis if given together with a high cholesterol diet and BSA injections or a regression of atherosclerotic changes if treated after atherosclerosis has developed. 63-67 BSA injections are Bovine Serum Albumine. It is an known method of inducing atherosclerosis in animals given a high cholesterol diet.
Semilunar valves, ascending & descending branches and aortic arch of a rat. (44). Above after 2 months on a cholesterol diet. Below after the same diet for 2 months but given PC after two months for two months.
Atherosclerosis was induced in animals with a 3 month atherogenic diet. The placebo group (pink line) developed atherosclerosis. The group given i.v. PC treatments showed marked regression of atherosclerosis (green line).
Human Studies 33, 41,46,68-77
A number of studies were done with EKG diagnostics. Depending on the PC dosage and the duration of treatment, an improvement of EKG findings could be achieved in many cases. Among them they found a dose-related disappearance of S-T depressions and reversal of previously negative T-waves to positive. These favourable changes went along with symptomatic relief of sternocardiac symptoms. Exercise tolerance as tested on the bicycle ergometer improved. The phase until S-T depression occurred became longer, with the depressions themselves being less distinct.
Other studies looked at the frequency of angina pectoris attacks and Nitroglycerine consumption. The investigations of Almazov et al. included 34 male patients suffering from ischaemic heart disease and angina pectoris of stages III-IV.
They received 500 mg/d of intravenous PC for a period of 14 days. 20 of the 34 patients reported an absence of anginal attacks already at the end of the first and beginning of the second week of treatment. The other 14 patients experienced a reduction of attacks from 8 to 10 per day to 1 to 3 attacks per day, with the severity decreasing as well. Daily nitro-consumption therefore, could be reduced to 2 to 5 doses from the initial 8-10 doses. It’s important though to realize that the fast decline of symptoms has to do with the improved flow capability of the RBCs and the reduced aggregation of platelets.
Mean incidence of anginal attacks per week and consumption of nitro-glycerine per week for patients with diminished coronary blood flow rates before and during a 6-week treatment with PC.(n=507) (73)
In a trial group of Almazov et al. the mean walking distance without stopping or having to use Nitroglycerine was increased from 30-50 meters to 3000 meters.
Fast CT Calcium Score Reduction
There are before and after reports of a significant reduction in Calcium Score and Volume as measured by Fast CT. However, to this day there is no study. If you have before and after Fast CT results, you can contact our webmaster at firstname.lastname@example.org to submit them. Dr. Baxas will compile them and publish the results on this website.
1 Salvioli, G. et al. Il Fegato 21 (1975) 5-25 and: 4th Int.Sympos.Atheroscl. Tokyo 1976 and: Diab.Obes.Hyperlipoprot. Cupaldi, V. et al. (eds.) Academic Press:New York 1987
2 A.K. Horsch et al Vasa 15 (1986) 275-279
3 Djuric, D. D. Manojlovic 1st Balkan Diabetes Congress, Beograd 1973
4 Fasoli, A. Therap. Select. Risk/Benefit Assess. Hypolip. Drugs, G. Ricci et al. (eds.) Raven Press: New York 1982, 257-262
5 Kataoka, A. Gendai no Shinryo 22 (1980) 1591-1583
6 Blaton, V. et al. Artery 2 (1976) 309-325
7 Blaton, V. et al. Bull Soc.Pharm.Lille (1980) 3-4, 191-198
8 Gaskina, Tl.K. et al. Voprosy meditsiniskoi khimii 3331 (1987) 96-99
9 Takahashi, S. Shinryo to Shinyaku 17 (1980) 3051-3064
10 Desreumaux, C., E. Dedonder, P. Dewsilly, G. Sezille, J.C. Fruchart: Effects of unsaturated fatty acids in phospholipids on the in vitro activation of the lipoprotein lipase and the triglyceride lipase Drug Res. 29 (1979) 1581-1583
11 A.K. Horsch et al Vasa 15 (1986) 275-279
12 Fasoli,A.: Clinical evaluation of polyenephosphatidylcholine (PPC) – effects on the serum lipid and lipoprotein patterns. Therap. Select. Risk/Benefit Assess. Hypolipid. Drugs (G. Ricci, R. Paoletti, Pocciari, Poggiolini, Eds. ) Raven Press, New York (1982) 257-262
13 Blaton, V., F. Sateway, D. Vandamme, B. Decercq, H. Peeters; Effect of polyunsaturated phosphatidylcholine on human types II and IV hyperlipoproteinemias. Artery 2 (1976) 309-325
14 Blaton, V.H.: L'influence des acides gras poly-insaturés sur les lipides et les lipoprorteinesplasmatiques. Bull.Soc. Pharm. Lille (1980) 3-4, 191-198
15 Caruzzo, C., L. Enrico-Bena, R. Camaghi: Variazioni delle frazioni lipidiche del siero di aterosclerotici indotte dello fosfatidilcholino. Minerva Med. 60 (1969) 1643-1652
16 Peeters, H. , V. Blaton, B. Declercq, D. Vandamme: The Effect of essential phospholipids in the lipid and fattz acid pattern of lipoproteins in type II patients. 4. Int. Symp. Drugs Affect Lipid Metab. Philadelphia, September 1971
17 Peeters, H. , V. Blaton, F. Soetewey, B. Declercq, V. Vandamme: Wirkung der essentiellen Phospholipide auf Plasmalipide und Fettsäuren beim Typ II der Hyperlipoproteinämie. Münch. Med. Wschr. 115 (1973) 1358-1362
18 Peeters, H., B. Declercq, V. Blaton: Longitudinal effect of polyunsaturated phosphatidylcholine on the human hyperlipoproteinaemia. 5th Int. Symp. Drugs Affect. Lipid Metabol, Milan Sept. 1974
19 Petruzzi, E. , C. Chiostri: Analisi gas-cromatografica delle varie frazioni lipidiche del siero e funzionalita piasrinica in soggetti diabetici con complicanze vascolari. 5. Nat. Congr. Ital. Soc. Diabetol., March 1974
20 Murakami M., H. Sekimoto Unpublished reports no. 148 745
21 P. Saba et al Curr.Therap.Res 24 (1978) 299-306
22 Dewailly, P., S. Moulin, J.P. Rouget, G. Sezille, J. Jaillard: Wirkungen des Polyenylphosphatidycholins auf Lipoproteine bei Patienten mit Hypercholeterinämie. Med. Welt 36 (1985) 367-369
23 Horsch, A.K., I. Majolk, C.C.Heuck, E. Göpfert: Influence of polyenphosphatidylcholine on serum lipids of patients with hyperlipoproteinemia. VASA 15 (1986) 251-256
24 Murakami, M., H. Sekimoto: Klinische Erfahrungen mit EPL. Research Report No. 840745 (1984)
25 Saba, P., F. Galeone, F. Savadorini, E. Pagliai, G. Guidi, A. Scalabrigo: Effects of soybean polyunsaturated phosphatdiylcholine on hyperlipoproteinemia. Curr. Therap. Res. 24 (1978) 299-306
26 Izumi, H.: Effect of plyenephosphatidylcholine on abnormality of lipid metabolism in diabetic patients. 11. Proceed. Jap. Atheroscl. Soc. Tokyo 1979
27 Arsenio, L., P. Bodria, G. Magnati, A. Strata: Studio dell' attivita terapeutica della fosfatidilcolina in diabetici con associata iperdislipidemia. Clin. Ter. 114 (1985) 117-127
28 Blagosklonov, A.S., E.S. Nalivaiko, G.A. Bykov, Y.T. Kaminka, E.M. Khalolov: Hemosorption and essential phospholipids as part of combined treatment in coronary patients. Kardiolgiya 26 (1974) 35-38
29 Cinosi, V.: Fosfatidilcolina e colesterolo delle lipoproteine plasmatiche dopo terapia con EPL. Sympos. Epidem. Prevenz dell' Arterioscl. Cagliari, 1982 and:
Influenza della somministrazione di EPL sulle variazioni delle HDL2 e HDL3. Round Table Phospholip. Atheroscleros. Rome, Nov. 1984
30 Fakhri, O., E. Popov, Z. Gabbasov, H. Kurdanov, I. Gavrilov: Effect of Lipostabil on serum lipid levels, and platelet aggregation in patients with ICD and hyperlipoproteinemia. 8th Int. Symp. on Atherosclerosis, Rome Oct. 1988
31 Iwasaki, Y., M. Aono, N. Aoki: Effects of polyenephosphatidylcholine on lipoprotein metabolism. Jap. Arch. Intern. med. 29 (1982) 11-15
32 Maeda, A., K. Kondo, S. Tsuyama, M. Nagasaka, M. Burin, Y. Iida, T. Nomato: The effect of polyenphosphatidylcholine on HDL cholesterol in atherosclerosis. Gendai No Shinryo 22 (1980) 189-192
33 Serkova, V.K.: Dynamics of blood lipids, parameters of lipid peroxidation and energy metabolism in patients with ischemic heart disease treated with Essentiale, Klin.Med. (Moscow) 64 (1986) 91-85
34 Grebenev, A.L., S.S. Katsev, V.S. Golochevskaja, L.P. Geniya: Lipostabil in the treatment of hyperlipidemia and the possibility of its correcting effect on liver function. Lipostabil Symp. Moscow, Nov. 1984, 47-48
35 Horsch, A.K., I. Majolk, C.C. Heuck, E. Göpfert:Influence of polyenphosphatidylcholine on serum lipids of patients with hyperlipoproteinemia. VASA 15 (1986) 251-256
36 Kolde G., E. Kessler, N. van Husen, M. Themann: Feinstrukturell-morphologische Untersuchungen an der cholestatischen Rattenleber unter Behandlung mit Polyenylphosphatidylcholine. Z. Gastroenterol. 16 (1978) 625-693
37 Kalmykova, V.I., E.b. Zakharova: Disorders of fatty acid composition and lipid peroxidation processes in chronic ischaemic heart disease. Sov.Med. 4 (1989) 5-8
38 Takahashi, S.: Treatment of abnormality of lipid and lipoprotein metabolism-Effect of polyenylphosphatidylcholine. Shinryo to Shinyaku 17 (1980) 3051-3084
39 Gurevich, V.S., W.W. Jeliseev, L.W. Schatilina, J.B. Krylova: Wirkung der essentiellen Phospholipide auf die Intensität der Lipidperoxidation im Myokard während experimenteller Hypoxie und Reoxygenierung (Reperfusionssyndrom). Essentielle Phospholipide in der Therapie der Atherosklerose (B.B. Bondarenko Ed.) Leningrad (1989) 76-81
40 Yoritsune, S., T. Mozai: Effect of polyenylphosphatidylcholine on platelets and red blood cell function. Gendai no Shinryo 22 (1980) 836-842
41 Almazov, V.A., V.S, Gurevich, E.I. Krasilnikova, B.B. Bondarenko: Effects of LIpostabil on blood lipids, platelet function and macrophage function in patients with ischaemic heart disease. Lipostabil Symp. Moscow, Nov 1984
42 Cocheri S., M. Alessandri, V. de Rosa: Platelets and contact activation of blood clotting. Influence of some aggregation inhibitros. Acta Med. Scand 190 (Suppl. 525) (1971) 253-256
43 Belousova, S.S., S.I. Bogoslovskaya, L.M. Silagina: Plasma lipoproteins and platelet function in patients with ischaemic heart disease treated with essential phospholipids. Kardiologiya 25 (1985) 112-115
44 Galli, C., E. Tremoli, E. Giani, P. Maderna, G. Gianfranceschi, C.R. Sirtori: Oral polyunsaturated phosphatidylcholine reduces platelet lipid and cholesterol contents in healthy volunteers. Lipids 20 (1985) 561-566
45 Kukes, V.G., E.A. Senik, E.T. Gneushev, S.A. Potekaeva, N.M. Milovanova, F.M. Slavutskaya, V.P. Litvinova: The use of preparation Essentiale in patients with chronic ischaemic heart diaease. Kardiologyia (Moscow) 18 (1978) 70-82
46 Kukes, V.G., E.A. Senik, E.N. Slavinskaya, T.A. Zolotova: On the mechanism of action of Lipostabil forte. Lipostabil Symp. Moscow, Nov 1985
47 Merchan, R., G. Dona: Microcirculation and haemorrheology studies on polyunsaturated phosphatidylcholine (EPL, Lipostabil) in teh aged. Clin. Trials J. 21 (1984) 517-525 and:
Merchan, R., G. Dona, A. Ribeiro: Fosfatidilcolina polinsatura e vasculopatie nell' anziono: studio capillaroscopico, emostaseologico e ermoreologico. Acta Gerontol. 34 (1984) 242-253
48 Cafiero, M., G. Buono, G. Rocca, P. Sensale: Contributo clinico in merito all' efficacia die due farmaci ad azione antiaggregante piastrinica. Clin. Ter. 72 (1975) 563-576
49 Numano, Furuta, Mitani, Aoyagi, Maruyama, Yashima, Numano: The effect of EPL on platelet aggregation and prostanoid. Kiso to Rinsho 20 (1986) 627-631
50 Ehrly, A.M., R. Blendin: Influence of essential phospholipids on the flow properties of the blood. Phosphatidylcholine-Biochemical and Clinical Aspects of Essential Phospholipids (H. Peeters, Ed.) Springer Press, Berlin-Heidelberg-New York (1976) 228-236
51 Salvioli, G., R. Salati, G. Rioli, R. Lugli, P. Rivasi: Le anomalie morfologiche eritrocitarie in corso di colestasi (effetto della fosfatidilcolina polinatura sulle spur cells), Il Fegato 21 (1975) 5-25 and:
Salvioli G.,: Effect of polyunsaturated phosphatidylcholine infusion on lipoprotein and red cell lipid composition in patients with spur cell anemia. Diab. Obes. Hyperlipidemias (V. Cupaldi et al. Eds.) Academic Press, New York (1978) 305-310
52 Salvioli, G. , G. Rioli, R. Lugli, R. Salati: Membrane lipid composition of red blood cells in liver disease: regression of spur cell anemia after infusion of polyunsaturated phosphatidylcholine, Gut 19 (1978) 844-850
53 Intensive Care Med. 2004 Oct;30(10):1974-8. Epub 2004 Mar 26. Effects of polyenylphosphatidylcholine on cytokines, nitrite/nitrate levels, antioxidant activity and lipid peroxidation in rats with sepsis. Demirbilek S, Ersoy MO, Demirbilek S, Karaman A, Akin M, Bayraktar M, Bayraktar N.
54 Meijuan Cheng, Hongying Pan, Yining Dai, Jiajie Zhang, Yongxi Tong, Yicheng Huang, Mingshan Wang & Haijun Huang (2018) Phosphatidylcholine regulates NF-κB activation in attenuation of LPS-induced inflammation: evidence from in vitro study, Animal Cells and Systems, 22:1, 7-14, DOI: 10.1080/19768354.2017.1405072
55 Avogaro,P., G. Bittolo-Bon, G. Cazzolato: A role for phosphatidylcholine in reducing the damage of oxidized low density lipoproteins. In: Phosphatidylcholine: Effects on cell membranes and transport of cholesterol (A.I. Archakov and K.J. Gundermann, Eds), Wbn Press Bingen/Rhine (1989) 65-68
56 Benzi, G., F. Marzatico, O. Pastoris, R.F. Villa: Cerebral enzyme antioxidant system. Influence of aging and phosphatidylcholine J. Neuroscience Res. 23 (1990) 120-128
57 DOI: 10.1111/j.1530-0277.1997.tb03776.x Polyenylphosphatidylcholine Decreases Alcohol-Induced Oxidative Stress in the Baboon. Charles S. Lieber*, Maria A. Leo, Semyon I. Aleynik, Maria K. Aleynik, Leonore M. DeCarli
58 Barbarino, F., A. Suciu, E. Neumann, M. Domokos, St. Tamas, A. Nicoara, O.A. Brudan, M. Campeanu, A. Ban, S. Cotul, C. Stroila, E. Toganel, K.J. Gundermann: Effect of essential phospholipids in chronic hepatitis and on immunological processes. Therapiewoche Oesterreich 4 (1989) 155-162
59 Hantak, I., M. Boca, M.Mikulecky, D. Stancek: Essential Phospholipids in the treatment of chronic hepatitis B viral infections. Internal Medicine 36 (1990) 1164-1171
60 Wojcicki, J., T. Dutkiewicz, J. Gieldanowski, L. Samochowiec, B. Barcew-Wiszniewska, L. Rozewicka, D. Wira, t. Wesolowska, B. Torbus-Lisiecka, B. Gonet, S. Juzwiak, D. Kadlubowska: Essential phospholipids modify immunological functions and reduce experimental atherosclerosis in rabbits. Atherosclerosis 93 (1992) 7-16
61 Bowyer, D.E., J.W. Fox, E. Muir: Hemmung der Endozytose in arteriellen glatten Muskelzellen durch hochungesättigtes Phosphatidylcholine. Med.Welt 30 (1979) 1447-1448
62 Shirai, K., Y. Saito, A, Kumagai: The role of modified high density lipoproteins with polyenphosphatidylcholine vesicles. Jpn. Arterioscl. 11 (1983) 1045-1049
63 Samochowiec, L. et al. Atherosclerosis 23 (1973) 305-331
64 Howard,A.N., J. Patelski, D.E. Bowyer, G.A. Gresham: Atherosclerosis induced in hypercholesterolaemic baboons by immunological injury; and the effects of intravenous polyunsaturated phosphatidylcholine. Atherosclerosis 14: 17-29,1971
65 Patelski, J., D.E. Bowyer, A.N. Howard, I.W. Jennings, C.J.R. Thorne: Modification of enzyme activities in experimental atherosclerosis in the rabbit Atherosclerosis 12 (1970) 41-53
66 14 Adams, Abdulla, Bayliss, Morgan J Pathol Becteril 1967 Jul; 94(1):77-78
67 Rozewicka, L., D. Kadlubowska: Effect of essential phospholipids on the lipid content in the liver and myocardium of rats fed a high fat diet. Folia boil. (Krakow) 26 (1978) 249-255
68 Itkina, L.D. et al. The use of Lipostabil in geriatric practice. Lipostabil Symposium Moscow, Nov 1984
69 Mohamedi, C. Fortschr. Med. 89 (1971) 893
70 Obata, K. et al. Unpublished report no. 840 754
71 Pristautz, H. et al. Wiener Med.Wschr. 124 (1974) 644-648
72 Seki, H. et al. Gendai Iryo 6 (1972) 599-618
73 Merchan, R. et al. Acta Geront. 34 (1984) 242-253 and : Clin.Trials J. 21 (1984) 517-525
74 Almazov, V.A. et al. Kardiologiya 26 (1986) 39-42
75 Balansard, P. Unpublished report no. 842 301
76 Idu, S.M. et al. Ueber die Wirksamkeit essentieller Phospholipide bei der Behandlung der Atherosklerose. Viata Medicala 17 (1970) 297-305
77 Hevelke, G., Th. Högn, W. Haase, V. Böhlau: Ergebnisse einer mulizentrischen Studie mit Lipostabil. Med. Welt. 31 (1980) 593-602